[1]权浩浩,于小勇,程小红,等.血清抗M型磷脂酶A2受体抗体检测在膜性肾病诊断中的价值研究*[J].陕西医学杂志,2020,49(6):755-758.[doi:DOI:10.3969/j.issn.10007377.2020.06.029]
点击复制

血清抗M型磷脂酶A2受体抗体检测在膜性肾病诊断中的价值研究*
分享到:

《陕西医学杂志》[ISSN:1000-7377/CN:61-1281/TN]

卷:
49
期数:
2020年6期
页码:
755-758
栏目:
临床检验
出版日期:
2020-06-05

文章信息/Info

作者:
权浩浩1于小勇2程小红2田 耘2张 宇2张 鹏2宋阿苗2延 佩2赵 凯3张晓凤2△
1.陕西中医药大学(咸阳 712046); 2.陕西省中医医院肾病科(西安 710003); 3.陕西中医肝肾病医院(西安 710016)
关键词:
抗M型磷脂酶A2受体抗体 特发性膜性肾病 继发性膜性肾病 诊断 价值
分类号:
R446.8
DOI:
DOI:10.3969/j.issn.10007377.2020.06.029
文献标志码:
A
摘要:
目的:研究抗M型磷脂酶A2受体抗体在膜性肾病患者血清中的表达情况,明确抗磷脂酶A2受体抗体检测在膜性肾病诊断中的价值。方法:选取肾活检证实的膜性肾病患者60例,包括特发性膜性肾病40例,继发性膜性肾病20例,上述患者均未经过糖皮质激素及免疫抑制剂治疗。并选择同期体检健康者20例为对照组。对各组人群的24 h尿蛋白定量、白蛋白、血肌酐、总胆固醇、甘油三酯等指标进行比较。采用双抗体两步夹心酶联免疫吸附法检测各组人群血清中抗M型磷脂酶A2受体抗体的浓度。结果:特发性膜性肾病与继发性膜性肾病组24 h尿蛋白、血清白蛋白、血肌酐、总胆固醇、甘油三酯水平比较均无统计学差异; 特发性膜性肾病患者血清抗M型磷脂酶A2受体抗体阳性率为75%,抗体滴度为(44.26±7.81)RU/ml,其抗体以IgG4型为主; 继发性膜性肾病患者血清抗M型磷脂酶A2受体抗体阳性率为15%,抗体滴度为(11.39±6.78)RU/ml,其抗体IgG1、IgG2和IgG3型均可见到,抗体滴度两组比较有统计学差异(P<0.05)。结论:血清抗M型磷脂酶A2受体抗体检测在特发和继发性膜性肾病诊断和鉴别诊断中具有重要的指导价值。

参考文献/References:

[1] Wasserstein AG.Membranous glomerulonephritis[J].J Am Soc Nephro,1997,8(4):664-674.
[2] Segal PE,Choi MJ.Recent advances and prognosis in idiopathic membranous nephropathy[J].Adv Chronic Kidney Dis,2012,19(2):114-119.
[3] Yang L,Liu D,Liu Z,et al.Recent advances and prognosis in membranous nephropathy[J].Chinese Journal of Nephrology,2016,32(3):229-232.
[4] 王海燕.肾脏病学[M].3版.北京:人民卫生出版社,2008:1032-1042.
[5] Beck LH Jr,Bonegio RG,Lambeau G,et al.M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephmpathy.N Engl J Med,2009,361(1):11-21.
[6] Qin W,Beck LH Jr,Zeng C,et al.Anti-phospholipase A2 receptor antibody in membranous nephropathy.J Am Soc Nephrol,2011,22(11):1137-1143.
[7] 邹万忠.肾活检病理学[M].北京:北京大学医学出版社,2009:156-162.
[8] 贾利敏.不典型膜性肾病患者血栓弹力图与常规凝血试验相关性分析[J].陕西医学杂志,2018,47(12):1528-1531.
[9] Prunotto M,Carnevali ML,Candiano G,et al.Autoimmunity in membranous nephropathy targets aldose reductase and SOD2[J].J Am Soc Nephrol,2010,21:507-519.
[10] Glassock RJ.The pathogenesis of idiopathic membranous nephropathy:a 50-year odyssey[J].Am J Kidney Dis,2010,56(1):157-167.
[11] 张 翥,丁庆龙,李炳辰.继发性膜性肾病的病因与治疗[J].中国临床医生杂志,2019,47(9):1014-1016.
[12] Larsen CP,Messias NC,Silva FG,et al.Determination of primary versus secondary membranous glomerulopathy utilizing phospholipase A2 receptor staining in renal biopsies[J].Mod Pathol,2013,26(5):709-715.
[13] Hofstra JM,Beck LH Jr,Beck DM,et al.Anti-phospholipase A2 receptor antibodies correlate with clinical status in idiopathic membraneous nephropathy[J].Clin J Am Soc Nephrol,2011,6(6):1286-1291.
[14] Zhang R,Zheng ZY,Lin JS,et al.The continual presence of C3d but not IgG glomerular capillary deposition in stage Ⅰ idiopathic membranous nephropathy in patients receiving corticosteroid treatment[J].Diagnostic Pathology,2012,7:109.
[15] 周广宇,金 玲,于 晶,等.成人膜性肾病患者血清抗PLA2R抗体与病情的相关性[J].中华肾脏病杂志,2012,28(2):111-114.
[16] Huang CC,Lehman A,Albawardi A,et al.IgG subclass staining in renal biopsies with membranous glomerulonephritis indicates subclass switch during disease progression[J].Mod Pathol,2013,26(6):799-805.
[17] Du Y,Li J,He F,et al.The diagnosis accuracy of PLA2R-AB in the diagnosis of idiopathic membranous nephropathy:a meta-analysis[J].PLoS One,2014,9(8):e104936.
[18] Oh YJ,Yang SH,Kim DK,et al.Autoantibodies against phospholipase A2 receptor in Korean patients with membranous nephropathy[J].PLos One,2013,8(4):65-65.
[19] Beck LH Jr,Salant DJ.Membranous nephropathy:recent travels and new roads ahead [J].Kidney Int,2010,77(9):765-770.
[20] 曹鹏龙,李士军,郐婷婷,等.血清抗M型磷酯酶A2受体抗体与成人特发性膜性肾病的相关性[J].实用医学杂志,2014,30(15):2441-2444.
[21] 刘莎莎,桑晓红,刘 珍.特发性膜性肾病诊断及治疗研究进展[J].中华实用诊断与治疗杂志,2017,31(1):82-84.
[22] 董鸿瑞,王艳艳,王国勤,等.检测特发性膜性肾病肾小球IgG亚型沉积及磷脂酶A2受体表达的回顾性分析[J].中国实用内科杂志,2014,34(5):507-511.
[23] 祝爽爽,周树录,周朝敏,等.成人特发性膜性肾病肾组织M型磷脂酶A2受体1抗原的检测[J].南方医科大学报,2015,35(4):526-529.
[24] Nicola MV,Sede SM,Pozner R,et al.Phylogeography and palaeodistribution modelling of Nassauvia subgenus strongyloma(asteraceae):exploring phylogeographical scenarios in the Patagonian steppe[J].Ecology and Evolution,2014,4(22):4270-4286.
[25] 王爱春,沙文刚.特发性膜性肾病与M 型磷脂酶A2受体[J].中国中西医结合肾病杂志,2014,15(1):78-79.
[26] De Vriese AS,Glassock RJ,Nath KA,et al.A proposal for a serology-based approach to membranous nephropathy[J].J Am Soc Nephrol,2017,28(2):421-430.
[27] 曲逸伦,董哲毅,陈香美.膜性肾病诊断方式的演变[J].解放军医学杂志,2019,44(12):1067-1071.

相似文献/References:

[1]纪伟超,郭红英,李曼曼,等.人类白细胞抗原-DQA1、细胞色素P4503A5*3基因多态性与特发性膜性肾病遗传易感性关联性研究[J].陕西医学杂志,2024,(7):936.[doi:DOI:10.3969/j.issn.1000-7377.2024.07.015]
 JI Weichao,GUO Hongying,LI Manman,et al.Correlation between gene polymorphisms of HLA-DQA1 and CYP3A5*3 and genetic susceptibility of idiopathic membranous nephropathy[J].,2024,(6):936.[doi:DOI:10.3969/j.issn.1000-7377.2024.07.015]

备注/Memo

备注/Memo:
*国家重点研发计划项目(2019YFC1709404);陕西省卫生和计划生育委员会科研课题(2014D6);陕西省科技创新创业“双导师制”项目(2018JM7155)
更新日期/Last Update: 2020-07-28